DGLA-Induced Ferroptosis via ACSL4 in Acute Myeloid Leukemia: Mechanistic and Translational Insights

Study Background and Research Question

Acute myeloid leukemia (AML) remains a clinically challenging hematological malignancy characterized by high rates of relapse, mortality, and resistance to conventional chemotherapies. While most chemotherapeutics act by inducing apoptosis, the tendency of leukemic cells to evade apoptotic pathways contributes significantly to treatment failure. This has motivated a shift toward exploring alternative cell death mechanisms, such as ferroptosis—a regulated form of cell death driven by iron-dependent lipid peroxidation and distinct biochemical features. Despite advances in understanding ferroptosis in solid tumors, its regulatory mechanisms and therapeutic potential in AML are not well defined.

Key Innovation from the Reference Study

The reference study (Jiang et al., Translational Oncology, 2025) presents a pivotal advance: exogenous administration of dihomo-γ-linolenic acid (DGLA), a polyunsaturated fatty acid (PUFA), substantially induces ferroptosis in AML cells via acyl-CoA synthetase long-chain family member 4 (ACSL4)-mediated lipid metabolic reprogramming. By systematically profiling changes in lipid metabolism during ferroptosis, the authors establish ACSL4 as a metabolic gatekeeper that determines the susceptibility of AML cells to ferroptosis upon DGLA exposure. This mechanistic insight extends the current paradigm, suggesting dietary and metabolic interventions as adjuncts to classical chemotherapy in AML.

Methods and Experimental Design Insights

The study employed a multi-pronged approach:

• High-throughput targeted metabolomics: AML cell lines were analyzed for changes in fatty acid profiles during ferroptosis, revealing significant shifts in 12 fatty acids including DGLA, arachidonic acid (AA), and docosahexaenoic acid (DHA).
• Pharmacological and genetic manipulation: Exogenous DGLA was administered to cultured AML cells, and the functional role of ACSL4 was dissected using knockout models to determine its necessity for DGLA-induced ferroptosis.
• Cell death and viability assays: Ferroptosis induction was confirmed through established markers such as lipid peroxidation and reactive oxygen species (ROS) accumulation, with parallel assessments of cell viability.
• In vivo validation: Mouse models fed a DGLA-enriched diet were evaluated for leukemia cell growth and ferroptosis status, supporting translational relevance.

This integrative design allowed the authors to link metabolic perturbations to functional outcomes in both cellular and animal models, strengthening the physiological significance of their findings.

Core Findings and Why They Matter

The study establishes several key points:

• Lipid metabolic reprogramming is intrinsic to ferroptosis in AML: Targeted metabolomics identified profound alterations in PUFA profiles during ferroptosis, with DGLA levels specifically correlating with increased cell death.
• Exogenous DGLA is a potent ferroptosis inducer: DGLA alone was sufficient to trigger iron-dependent lipid peroxidation, ROS accumulation, and ultimately ferroptotic cell death in AML lines in vitro.
• ACSL4 is essential for DGLA-driven ferroptosis: Genetic ablation of ACSL4 significantly inhibited DGLA-induced ferroptosis, implicating this enzyme in the activation and incorporation of DGLA into phospholipid pools susceptible to peroxidation.
• Dietary DGLA restricts leukemia progression in vivo: Mice receiving a DGLA-enriched diet exhibited reduced leukemic burden and increased markers of ferroptosis, underscoring the translational potential of metabolic modulation.

These findings illuminate a previously underappreciated axis—dietary PUFA metabolism through ACSL4—as a modifiable determinant of ferroptosis sensitivity in AML. This may have far-reaching implications for overcoming chemotherapy resistance, particularly in cases where traditional pro-apoptotic approaches are ineffective.

Comparison with Existing Internal Articles

Recent internal resources have explored the intersection of autophagy, lipid metabolism, and ferroptosis in cancer models. For example, "Chloroquine Diphosphate: Mechanistic Insights and Future..." discusses how autophagy modulation by Chloroquine Diphosphate (4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine;phosphoric acid) can intersect with ferroptosis pathways, influencing cell survival and therapy response. Similarly, "Chloroquine Diphosphate: Integrating Autophagy Modulation..." highlights the mechanistic overlap between autophagy and ferroptosis in cancer research, drawing attention to the importance of TLR7/9 inhibition and cell fate modulation.

While these articles focus primarily on autophagy assays and the utility of Chloroquine Diphosphate as an autophagy modulator for cancer research, the current reference study extends this landscape by revealing how lipid metabolic reprogramming—specifically via ACSL4 and DGLA—can drive ferroptotic cell death in AML. This bridges metabolic and cell death pathways, suggesting that strategies which simultaneously modulate autophagy and ferroptosis may offer synergistic benefits in cancer research and therapy design.

Limitations and Transferability

Despite its comprehensive design, the study has several limitations:

• Cell line and model specificity: Most experiments were conducted in established AML cell lines and immunodeficient mouse models, which may not fully recapitulate the heterogeneity and microenvironmental factors of human AML.
• Mechanistic focus: The study centers on ACSL4 and DGLA, leaving open questions about the role of other lipid metabolic enzymes or alternative ferroptosis regulators in AML and other cancer types.
• Clinical translation: While dietary DGLA showed efficacy in preclinical models, the safety, optimal dosing, and feasibility of such interventions in humans remain untested.

Researchers should consider these limitations when extrapolating findings to primary patient samples or designing translational studies. The approach is, however, highly transferable for basic research aiming to dissect metabolic vulnerabilities in AML or to design combination therapies leveraging ferroptosis and autophagy pathways.

Protocol Parameters

• DGLA treatment: In vitro, exogenous DGLA was added to AML cell cultures at concentrations optimized for ferroptosis induction; details can be adapted based on cell type sensitivity and lipid uptake characteristics.
• ACSL4 knockout: CRISPR/Cas9-mediated gene editing or siRNA transfection was used to ablate ACSL4, confirming its role in DGLA-induced ferroptosis.
• Metabolomic profiling: Targeted liquid chromatography-mass spectrometry (LC-MS) was employed to quantify fatty acid alterations during ferroptosis.
• In vivo DGLA diet: Mice were fed a diet enriched with DGLA, with leukemia progression and ferroptosis markers monitored over time. Researchers should tailor dietary interventions to their specific animal models and experimental endpoints.

Research Support Resources

For investigators aiming to study the interplay between autophagy, ferroptosis, and lipid metabolism in AML or other cancer models, Chloroquine diphosphate (SKU A8628) is a well-characterized autophagy modulator and TLR7/9 inhibitor. Its established application in autophagy assays and chemotherapy sensitization workflows can provide a valuable comparative or combinatorial tool alongside ferroptosis-inducing strategies. For protocol optimization and troubleshooting in complex cell death assays, see recent workflow guides such as "Chloroquine Diphosphate in Autophagy Assays: Protocols & Pitfalls". Researchers are encouraged to leverage such resources to design robust, reproducible experiments that explore the multi-modal regulation of cell fate in cancer research.